Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLNO Soleno Therapeutics

Trading 02-09 14:45:22 EST

40.80

-0.73

-1.76%

High41.78	Low40.55	Vol506.86K
Open41.55	D1 Closing41.53	Amplitude2.96%
Mkt Cap2.19B	Tradable Cap1.83B	Total Shares53.71M
T/O20.73M	T/O Rate1.13%	Tradable Shares44.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLNO","market":"US","secType":"STK","nameCN":"Soleno Therapeutics","latestPrice":40.8,"timestamp":1770666312267,"preClose":41.53,"halted":0,"volume":506859,"delay":0,"changeRate":-0.0175776547074405,"floatShares":44870900,"shares":53710025,"eps":-1.75,"marketStatus":"Trading","change":-0.73,"latestTime":"02-09 14:45:22 EST","open":41.55,"high":41.78,"low":40.55,"amount":20726625.21711,"amplitude":0.029617,"askPrice":40.8,"askSize":268,"bidPrice":40.78,"bidSize":269,"shortable":3,"etf":0,"ttmEps":-1.75,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":41.53,"preHourTrading":{"tag":"盘前","latestPrice":41.3702,"preClose":41.53,"latestTime":"08:00 EST","volume":1,"amount":41.3702,"timestamp":1770642007116,"change":-0.1598,"changeRate":-0.003848,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":41.05,"preClose":41.53,"latestTime":"19:57 EST","volume":34851,"amount":1447127.6084,"timestamp":1770425863433,"change":-0.48,"changeRate":-0.011558,"amplitude":0.011558},"volumeRatio":0.334743,"impliedVol":0.9333,"impliedVolPercentile":0.7211},"requestUrl":"/m/hq/s/SLNO","defaultTab":"news","newsList":[{"id":"2608081528","title":"A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2608081528","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608081528?lang=en_us&edition=fundamental","pubTime":"2026-02-03 22:15","pubTimestamp":1770128107,"startTime":"0","endTime":"0","summary":"Why Soleno Therapeutics Is Back on Investors’ Radar\nSoleno Therapeutics (SLNO) is drawing fresh attention after describing 2025 as a transformational year, highlighting early traction for VYKAT XR, and flagging upcoming full financial results alongside a busy investor conference schedule.\nSee our latest analysis for Soleno Therapeutics.\nThe latest 9.75% 1 day share price gain to US$42.32 comes after management framed 2025 as transformational and highlighted early VYKAT XR traction. However,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/a-look-at-soleno-therapeutics-slno-valuation-after-vykat-xr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/a-look-at-soleno-therapeutics-slno-valuation-after-vykat-xr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2607347038","title":"Strategic Investment Fuels Confidence in Soleno Therapeutics’ Growth Outlook and Supports Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2607347038","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607347038?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:35","pubTimestamp":1769693738,"startTime":"0","endTime":"0","summary":"Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Soleno Therapeutics and keeping the price target at $120.00. Tyler Van Buren has g...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-investment-fuels-confidence-in-soleno-therapeutics-growth-outlook-and-supports-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-investment-fuels-confidence-in-soleno-therapeutics-growth-outlook-and-supports-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2607080612","title":"Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607080612","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607080612?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:15","pubTimestamp":1769692533,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Guggenheim maintained a Buy rating on Soleno Therapeutics, with a price target of $106.00. The company’s share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-soleno-therapeutics-slno-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-soleno-therapeutics-slno-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2607808740","title":"Soleno Therapeutics to Participate in Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2607808740","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607808740?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:00","pubTimestamp":1769691600,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Jan.  29, 2026  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228545/0/en/Soleno-Therapeutics-to-Participate-in-Upcoming-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2606608297","title":"Soleno Therapeutics Boosts Executive Pay and Severance Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=2606608297","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606608297?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:52","pubTimestamp":1769413979,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. has approved updated executive compensation arrangements for its named executive officers, including increases to base salaries for fiscal year 2026, cash bonuses for fiscal year 2025, and new equity awards. The company also adopted an Executive Severance Plan covering all Vice Presidents and above. Under the plan, executives terminated without cause or for good reason outside of a change in control period will receive severance payments based on months of base salary, target bonus percentage, and COBRA coverage, with equity acceleration only applying to the CEO. During a change in control period, executives are eligible for enhanced benefits, including longer severance periods, higher bonus percentages, COBRA coverage, and full acceleration of outstanding equity awards. For example, the CEO is entitled to 24 months of salary and COBRA coverage, a 150% target bonus, and 100% equity acceleration if terminated during a change in control period, while other C-suit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL7kHRzd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2605898972","title":"Soleno Therapeutics Updates Executive Compensation and Severance Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2605898972","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605898972?lang=en_us&edition=fundamental","pubTime":"2026-01-24 06:45","pubTimestamp":1769208355,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics ( ($SLNO) ) just unveiled an announcement. On January 21, 2026, Soleno Therapeutics’ board, following a review by its independe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-updates-executive-compensation-and-severance-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-updates-executive-compensation-and-severance-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2605945415","title":"Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2605945415","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605945415?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:30","pubTimestamp":1769092212,"startTime":"0","endTime":"0","summary":"Fourth quarter 2025 guidance puts revenue expectations in focus\nSoleno Therapeutics (SLNO) has put out preliminary unaudited revenue guidance for the fourth quarter of 2025, expecting net revenue between US$90 million and US$92 million, providing a fresh reference point for investors tracking the stock.\nSee our latest analysis for Soleno Therapeutics.\nAt a share price of US$43.56, Soleno Therapeutics has seen a 31.57% 3 month share price decline and an 11.79% 1 month share price decline, yet...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/soleno-therapeutics-slno-valuation-checked-after-new-q4-2025","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/soleno-therapeutics-slno-valuation-checked-after-new-q4-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2604838190","title":"Soleno Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2604838190","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604838190?lang=en_us&edition=fundamental","pubTime":"2026-01-20 19:58","pubTimestamp":1768910280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLNO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 20, 2026 06:58 ET (11:58 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO"],"gpt_icon":0},{"id":"2604973181","title":"Soleno Therapeutics: Strong VYKAT XR Outperformance, Solid Balance Sheet, and Global Growth Optionality Drive Higher Buy-Rated Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2604973181","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604973181?lang=en_us&edition=fundamental","pubTime":"2026-01-20 19:37","pubTimestamp":1768909042,"startTime":"0","endTime":"0","summary":"Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Soleno Therapeutics. The associated price target was raised to $120.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/soleno-therapeutics-strong-vykat-xr-outperformance-solid-balance-sheet-and-global-growth-optionality-drive-higher-buy-rated-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/soleno-therapeutics-strong-vykat-xr-outperformance-solid-balance-sheet-and-global-growth-optionality-drive-higher-buy-rated-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"1130640668","title":"Stock Track | Soleno Therapeutics Plummets 5.06% Intraday After Baird Cuts Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1130640668","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130640668?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:18","pubTimestamp":1768317517,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) saw its shares drop sharply by 5.06% during Tuesday's intraday trading session. The decline followed a negative adjustment by Baird, which lowered its target price for the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLNO"],"gpt_icon":0},{"id":"2603976638","title":"Cantor Fitzgerald Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603976638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603976638?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:37","pubTimestamp":1768315054,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Soleno Therapeutics today and set a price target of $123.00. Kluska covers the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-soleno-therapeutics-slno-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-soleno-therapeutics-slno-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2603168143","title":"Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603168143?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:46","pubTimestamp":1768308417,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Soleno Therapeutics, with a price target of $106.00. Accordin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/soleno-therapeutics-slno-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/soleno-therapeutics-slno-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1894683348.USD","LU0683600562.USD","LU0052756011.USD","IE00B7SZLL34.SGD","LU0320765489.SGD","LU0742534661.SGD","LU0251142724.SGD","BK4588","LU1280957306.USD","LU0128525689.USD","LU0980610538.SGD","LU0130517989.USD","LU0787776722.HKD","LU0130102774.USD","LU0942090050.USD","LU0971096721.USD","LU1267930573.SGD","LU0314106906.USD","LU2361045086.USD","LU0417517546.SGD","BK4501","LU0310799852.SGD","LU1363072403.SGD","BK4559","LU0256863811.USD","LU0289960550.SGD","LU0868494617.USD","LU0149725797.USD","LU2236285917.USD","LU1035773651.USD","SLNO","BK4504","IE00B19Z3581.USD","LU0208291251.USD","LU1506573853.SGD","LU1201861249.SGD","BK4585","LU0310800379.SGD","LU0310800965.SGD","LU1668664300.SGD","LU0128525929.USD","LU0251131958.USD","BK4207","LU0175139822.USD","LU2461242641.AUD","LU0477156953.USD","LU0048573561.USD","LU2361044865.SGD","IE0002270589.USD","LU2361044949.HKD"],"gpt_icon":0},{"id":"2603576317","title":"Soleno Therapeutics: Sustained U.S. Vykat XR Outperformance and European Upside Support Buy Rating and $100 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2603576317","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603576317?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:36","pubTimestamp":1768271770,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Kate Dellorusso maintained a Buy rating on Soleno Therapeutics yesterday and set a price target of $100.00. Kate Dellorusso...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/soleno-therapeutics-sustained-u-s-vykat-xr-outperformance-and-european-upside-support-buy-rating-and-100-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/soleno-therapeutics-sustained-u-s-vykat-xr-outperformance-and-european-upside-support-buy-rating-and-100-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2603282965","title":"Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2603282965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603282965?lang=en_us&edition=fundamental","pubTime":"2026-01-13 02:55","pubTimestamp":1768244125,"startTime":"0","endTime":"0","summary":"Wolfe Research lowered the firm’s price target on Soleno Therapeutics (SLNO) to $60 from $75 and keeps an Outperform rating on the shares. The firm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-60-from-75-at-wolfe-research-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-price-target-lowered-to-60-from-75-at-wolfe-research-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0},{"id":"2602241541","title":"BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2602241541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602241541?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:40","pubTimestamp":1768232404,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL6N3YD0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APH","WMT","BAC","WBD","ZYME","HL","JILL","CAT","FERG","AEO","SLNO","AFRM","OMF","AGCO","SCCO","AKAM","ABNB","CRH","EPD","BIRK","CDE","ALB","SHAK","CMI","URI","XYZ","MRNA","LYRA","SLM","SYF","JBHT","SEZL","URBN","ATRA","SNCY","KLAR","SRRK","ANF","MDLN","VG","NEM","CRWD","AWK","JCAP","QXO"],"gpt_icon":1},{"id":"2602546946","title":"Soleno Therapeutics Reverse Premarket Gains, Last Down 1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602546946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602546946?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:36","pubTimestamp":1768228571,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD1MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2602351019","title":"Soleno Therapeutics Preliminary Q4 Net Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2602351019","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602351019?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:09","pubTimestamp":1768223399,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics  reported preliminary Q4 net revenue Monday of $90 million to $92 million.Analysts surveyed by FactSet expect $83.3 million.The biotech company also said it has achieved profitability and positive cash flow and reported preliminary cash, cash equivalents and marketable securities of $500 million as of Dec. 31.Shares of the company were up more than 3% in recent Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLNO"],"gpt_icon":0},{"id":"2602851417","title":"Soleno Therapeutics Projects 2025 Net Revenue of Up to $191 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851417","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851417?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:03","pubTimestamp":1768219438,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. has reported select preliminary financial results for the fourth quarter and full year 2025, highlighting significant growth following the U.S. launch of VYKAT XR. The company expects preliminary unaudited full-year 2025 net revenue from U.S. sales of VYKAT XR to range between $189 million and $191 million. Fourth quarter net revenue is projected to be between $90 million and $92 million. Since the launch in the second quarter, Soleno has received 1,250 new patient start forms for VYKAT XR, representing approximately 12.5% of the total U.S. addressable market for the treatment. The company credits the strong performance to the successful launch and rapid market uptake of VYKAT XR, marking a transformational year for Soleno Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL4xxXnt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","SG9999014005.SGD","LU2210149790.SGD","SLNO","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","BK4139","SG9999014021.USD"],"gpt_icon":0},{"id":"2602851424","title":"Soleno Therapeutics Inc  Q4 REV View $81.7 Mln -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851424?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219212,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9KBZYW:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2602514517","title":"Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514517?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA9KBZYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLNO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.soleno.life","stockEarnings":[{"period":"1week","weight":0.077},{"period":"1month","weight":-0.0644},{"period":"3month","weight":-0.1294},{"period":"6month","weight":-0.4957},{"period":"1year","weight":-0.1854},{"period":"ytd","weight":-0.103}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.026118},{"month":2,"riseRate":0.333333,"avgChangeRate":0.239819},{"month":3,"riseRate":0.636364,"avgChangeRate":0.007758},{"month":4,"riseRate":0.454545,"avgChangeRate":0.050237},{"month":5,"riseRate":0.545455,"avgChangeRate":0.074125},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.071619},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.051924},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014863},{"month":9,"riseRate":0.454545,"avgChangeRate":0.409781},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.115533},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.012609},{"month":12,"riseRate":0.333333,"avgChangeRate":0.051862}],"exchange":"NASDAQ","name":"Soleno Therapeutics","nameEN":"Soleno Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Soleno Therapeutics,SLNO,Soleno Therapeutics股票,Soleno Therapeutics股票老虎,Soleno Therapeutics股票老虎国际,Soleno Therapeutics行情,Soleno Therapeutics股票行情,Soleno Therapeutics股价,Soleno Therapeutics股市,Soleno Therapeutics股票价格,Soleno Therapeutics股票交易,Soleno Therapeutics股票购买,Soleno Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}